Establishment of SOPs for in vitro and in vivo models to assess sigma-1 receptor ligands
WG3 aims are to design and implement SOPs in order to ensure compliance of SIGMA-1 EUROPE procedures and processes with applicable national and EU regulations and international standards, as well as to meet ethical and customer requirements. This will ensure traceability and continuous improvement of quality, efficiency, performance and reputation of SIGMA-1 EUROPE. In addition, Short Term Scientific Missions (STSMs) will be used to harmonise the protocols between participants and train a new generation of researchers to build new skills.
Leader:Dr. Enrique J. Cobos
Co-leader:Prof. Emanuele Amata
Tasks and Activities
Task. 3.1
Identification of a model for the development of sigma-1 receptor ligands
Task. 3.2
Identification of the most appropriate in vitro and in vivo methods to test sigma-1 receptor ligands
Task. 3.3
Identification of optimal safety profile for sigma-1 receptor drug development
Task. 3.4
Organise Short Term Scientific Missions (STMs)
Task. 3.5
Organise a workshops and training schools in advanced techniques
Deliverables
D3.1
Development of the most appropriate in silico, in vitro and in vivo methods to evaluate sigma-1 receptor ligands (protocols, articles, databases)
D3.2
Implementation of SOPs and harmonized protocols
D3.3
Identification of optimal safety profile for sigma-1 receptor drug development (reports, articles)